Innovative drugs were collectively higher in early trading. As of press release, Tiger Pharmaceuticals (03347) rose 11.11% to HK$31; Conoa-B (02162) rose 8.33% to HK$43.35; and Rongchang Biotech (09995) rose 7.8% to HK$29.7.
The Zhitong Finance App learned that innovative drugs were collectively higher in early trading. As of press release, Tiger Pharmaceuticals (03347) rose 11.11% to HK$31; Conoa-B (02162) rose 8.33% to HK$43.35; Rongchang Biotech (09995) rose 7.8% to HK$29.7; and Collumbotai Biotech (06990) rose 7.62% to HK$145.5.
According to the news, a “Draft for Solicitation of Comments on the Implementation Plan to Support the Development of Innovative Drugs in the Whole Chain” was circulated in the market yesterday. Its core is to comprehensively promote key aspects of R&D, approval, use, and payment of innovative drugs through policy guidance and support. However, this document has not been officially confirmed.
Some brokerage firms pointed out that this document is of great significance to the innovative drug industry. Specifically, it is reflected in the payment side: giving full play to the guiding and driving role of financial resources in the development of innovative drugs; improving the price of innovative drugs and medical insurance access. Key regions are encouraged to set up special funds for supplementary payment of innovative drugs. Supply side: Promote the construction of new drug platforms; in terms of approval: tilt more approval resources towards high-value innovative drugs; shorten the time for communication meetings.